Clinical Trial Update: Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bevacizumab for recurrent sex cord-stromal tumors of the ovary; study completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Ovarian Epithelial Tumor
• Ovarian Granulosa Cell Tumor
• Ovarian Gynandroblastoma
• Ovarian Sertoli-leydig Cell Tumor
• Ovarian Sex Cord-stromal Tumor
• Ovarian Sex Cord-stromal Tumor of Mixed or Unclassified Cell Types
• Ovarian Sex Cord-stromal Tumor with Annular Tubules
• Ovarian Steroid Cell Tumor

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Malignant Ovarian Epithelial Tumor, Ovarian Granulosa Cell Tumor | Phase 2 | Status: COMPLETED | Results posted: 2015-06-10